Clinical Trial Update: Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating personalized prophylaxis with human-cl rhFVIII in severe hemophilia A has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• human-cl rhFVIII (recombinant factor VIII concentrate (human-cl rhFVIII))

Snippet

Sponsor: Octapharma | Conditions: Severe Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2019-12-03